Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

COMBINE Comparative signature of Marburg virus cell activation as a blueprint for the identification of antiviral targets against newly emerging viruses

Coordinator
Helmholtz-Zentrum Fur Infektionsforschung GmbH, Germany
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€7.3m
Total cost
€7.3m
Partners
7 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101191739

What the project is doing

In the project's own words, from its summary on CORDIS.

Identifying cellular attachment factors and functional receptors plays a critical part in developing an understanding of a newly emerging virus. However, the identification and therapeutic targeting of plasma membrane proteins critical for virus infection is often difficult due to the transient nature of virus-cell binding and the overall kinetics of the infection process. Our goal is to interrogate virus-host cell interaction and cellular uptake of Marburg virus (MARV), a highly pathogenic and clinically relevant member of the filovirus family.

To specifically target virus-plasma membrane interaction we will use a unifying inverted infection platform that allows us to halt and synchronize virus infection at the cell binding stage. Our approach is compatible with BSL-4 environment and multi-Omics technologies. It will allow us to identify the signature of virus-host cell activation, i.e., proteins involved in virus-cell entry in a tissue-specific manner. This screen will be complemented by an innovative combination of proteomics, virus-host cell interaction analysis and imaging approaches to pinpoint and characterize the involved cellular and viral proteins, their post-translational modifications and how they mechanistically concert in viral uptake.

Our unique combination of different technologies will lead to the identification of viral and cellular interaction partners which will in parallel be specifically targeted by high-throughput compound screening to identify small molecules that inhibit virus-receptor interaction. Moreover, we will use our gained knowledge of tissue-specific post-translational modifications to develop improved vaccine candidates as additional prophylactic countermeasures against MARV.

Our project will further deliver a blueprint experimental pipeline for the streamlined identification and antiviral targeting of proteins involved in the virus attachment process, a critical cornerstone of pandemic preparedness.

Topics

Who is involved

OrganisationCityCountryRole
Helmholtz-Zentrum Fur Infektionsforschung GmbHBraunschweigGermanyCoordinator
Vib VzwZwijnaarde - GentBelgiumParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Universitetet I OsloOsloNorwayParticipant
Institutul De BiochimieBucharestRomaniaParticipant
Karolinska InstitutetStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI